Stage III Vulvar Cancer Withdrawn Phase 2 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0028772 (Stage III Vulvar Cancer)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03220009Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal MelanomaTreatment